New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Intellia Therapeutics, Inc. (NTLA) vs Rapport Therapeutics, Inc. (RAPP)

Intellia Therapeutics, Inc. and Rapport Therapeutics, Inc. are both Biotechnology companies. Intellia Therapeutics, Inc. and Rapport Therapeutics, Inc. are of similar size ($1.4B and $1.3B). Rapport Therapeutics, Inc. has the higher net margin (0.00% vs −805.8%) and the higher return on invested capital (0.00% vs −195.3%). Across the 12 metrics below, Rapport Therapeutics, Inc. leads on 9 and Intellia Therapeutics, Inc. on 3.

Valuation

Metric NTLA RAPP Biotechnology median
P/E n/m n/m 8.26
P/S 25.31 n/m 9.20
P/B 2.18 2.88 2.09
Price to free cash flow n/m n/m 24.49
EV/EBITDA n/m n/m 0.67
EV/Sales 16.35 n/m 9.05
Earnings yield (35.08%) (13.42%) (34.24%)
Free cash flow yield (26.72%) (10.70%) (24.77%)

Profitability

Metric NTLA RAPP Biotechnology median
Gross margin 100.00% — 70.18%
Operating margin (821.24%) 0.00% 0.00%
Net margin (805.75%) 0.00% 0.00%
Free cash flow margin (676.38%) 0.00% 0.00%
Return on equity (62.60%) (33.33%) (51.58%)
Return on assets (46.63%) (31.55%) (45.91%)
Return on invested capital (195.32%) 0.00% 0.00%

Growth

Metric NTLA RAPP Biotechnology median
Revenue growth (TTM) (8.07%) — 7.20%
EPS growth (last fiscal year) 27.43% 24.34% 29.04%
Revenue growth, 5-year CAGR 3.13% — 9.48%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric NTLA RAPP Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 6.31 20.07 4.83
Net debt to EBITDA 1.06 3.91 1.01

Dividend

Metric NTLA RAPP Biotechnology median
Dividend yield — — 0.40%
Payout ratio — — —

Size

Metric NTLA RAPP Biotechnology median
Market cap 1.31b 1.40b 155.23m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack